{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=35", "query": { "condition": "Refractory Malignancy", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 5766, "total_pages": 577, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Malignancy&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T19:45:13.306Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02115035", "title": "A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Vermurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2014-08-27", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115035" }, { "nct_id": "NCT05400122", "title": "Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Hematologic Malignancy", "Rectum Cancer", "Acute Myeloid Leukemia", "Myelodysplastic Syndromes", "Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Hodgkin Lymphoma", "Non Hodgkin Lymphoma", "Myeloproliferative Syndrome", "Plasma Cell Myeloma", "Gastric Cancer", "Esophageal Cancer", "Esophagus Cancer", "Gastric Cancer, Metastatic", "Unresectable Esophageal Cancer", "Metastatic Esophageal Cancer" ], "interventions": [ { "name": "Vactosertib", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" }, { "name": "Natural Killer Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David Wald", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-09-09", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400122" }, { "nct_id": "NCT01836705", "title": "Effect of SAR302503 on ECG Activity in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant" ], "interventions": [ { "name": "SAR302503 (TG101348)", "type": "DRUG" }, { "name": "Placebo SAR302503", "type": "DRUG" }, { "name": "Panolosetron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2013-05", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2025-03-05", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 8, "location_summary": "Los Angeles, California • Augusta, Georgia • Detroit, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01836705" }, { "nct_id": "NCT02588651", "title": "A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Hepato-splenic T-cell Lymphoma", "Adult T-cell Leukemia/Lymphoma", "Enteropathy Associated T-cell Lymphoma", "NK T-cell Lymphoma" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deepa Jagadeesh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2016-06-17", "completion_date": "2024-10-14", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 4, "location_summary": "Detroit, Michigan • Hackensack, New Jersey • Cleveland, Ohio", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588651" }, { "nct_id": "NCT00187083", "title": "A Study of Children With Refractory or Relapsed ALL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Topotecan, dexamethasone, vincristine", "type": "DRUG" }, { "name": "E. coli Asparaginase, PEG-L-asparaginase", "type": "DRUG" }, { "name": "erwinia asparaginase", "type": "DRUG" }, { "name": "fludarabine, methotrexate, mercaptopurine", "type": "DRUG" }, { "name": "idarubicin, etoposide, cytarbine, teniposide", "type": "DRUG" }, { "name": "chemotherapy, intrathecal chemotherapy, steroid therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 40, "start_date": "1997-02", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2008-06-04", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00187083" }, { "nct_id": "NCT05956041", "title": "Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous T Cell Lymphoma", "Fungoides Mycosis Sezary Syndrome" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2023-12-06", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05956041" }, { "nct_id": "NCT00337194", "title": "SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "monoclonal antibody SGN-30", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" }, { "name": "vinorelbine tartrate", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-04", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2015-02-23", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00337194" }, { "nct_id": "NCT05332054", "title": "Long-Term Follow-up Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma, Non-Hodgkin", "Relapsed Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Lymphoma", "B Cell Lymphoma", "B-Cell Non-Hodgkin's Lymphoma", "Hematologic Malignancy", "Relapsed/Refractory Multiple Myeloma", "Relapsed/Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Caribou-sponsored investigational therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Caribou Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2022-03-16", "completion_date": "2041-12", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05332054" }, { "nct_id": "NCT06839456", "title": "Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "High Risk Acute Lymphoblastic Leukemia", "High Risk Acute Myeloid Leukemia", "Relapse Leukemia", "MDS (Myelodysplastic Syndrome)", "Relapsed Non-Hodgkin Lymphoma", "Acquired Aplastic Anemia", "Inherited BMF Syndrome", "Immunodeficiency", "Primary Immune Regulatory Disorder", "Hemoglobinopathies", "Bone Marrow Failure", "Inborn Errors of Metabolism", "HLH" ], "interventions": [ { "name": "Phase 1 Dose Level 1", "type": "DEVICE" }, { "name": "Phase 1 Dose Level 2", "type": "DEVICE" }, { "name": "Phase 1 Dose Level 3", "type": "DEVICE" }, { "name": "Phase 2 Maximum Tolerated Dose determined in Phase 1", "type": "DEVICE" }, { "name": "Phase 2 Established Dose from prior study, NCT03810196", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Month to 25 Years" }, "enrollment_count": 100, "start_date": "2025-03-21", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06839456" }, { "nct_id": "NCT03384654", "title": "A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Precursor Cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Peg-asparaginase", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "6-mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 47, "start_date": "2018-05-14", "completion_date": "2022-09-27", "has_results": true, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-11-12T19:45:13.306Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384654" } ] }